IP Library Granted Patent US 9,279,119
Granted Patent B2
US 9,279,119 · App. 14/225,518 · Granted Mar 8, 2016

Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof

Inventors: George Georgiou (Austin, TX); Everett Stone (Austin, TX)
Assignee: AEMase, Inc.
C12N9/88C12N9/96A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,279,119
App. No.
14/225,518
Granted
Mar 8, 2016
Kind
B2
Abstract

Methods and composition related to the engineering of a novel protein with methionine-γ-lyase enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase (CGL) comprising one or more amino acid substitutions and capable of degrading methionine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with methionine depletion using the disclosed proteins or nucleic acids.

Claims (12)

1. A nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising a variant of a primate cystathionine gamma-lyase, wherein the variant cystathionine gamma-lyase has methionine gamma-lyase activity, a sequence at least 95% identical to SEQ ID NO:1, and comprises amino acid substitutions at amino acid positions corresponding to positions 59, 119 and 339 of SEQ ID NO:1, the native human cystathionine gamma-lyase, said substitutions being i) E59V or E59N, ii) R119L and iii) E339V.

2. The nucleic acid of claim 1 , wherein the cystathionine gamma-lyase is human cystathionine gamma-lyase comprising SEQ ID NO:1 having the i) E59V or E59N, ii) R119L and iii) E339V substitutions.

3. The nucleic acid of claim 1 , wherein the variant primate cystathionine gamma-lyase has at least 98% sequence identity to the sequence of SEQ ID NO:1 having the i) E59V or E59N, ii) R119L and iii) E339V substitutions.

4. The nucleic acid of claim 1 , wherein the encoded polypeptide further comprises a heterologous peptide segment.

5. The nucleic acid of claim 1 , wherein the heterologous peptide segment is an XTEN peptide.

6. The nucleic acid of claim 1 , wherein the nucleic acid is codon optimized for expression in bacteria.

7. An expression vector comprising the nucleic acid of claim 6 .

8. A host cell comprising the nucleic acid of claim 6 .

9. The host cell of claim 8 , wherein the host cell is bacteria.

10. The host cell of claim 9 , wherein the host cell is an E. coli strain having deletions of genes ilvA and metA.

11. The nucleic acid of claim 1 , wherein the encoded polypeptide comprises amino acid substitutions at each of amino acid positions 59, 119 and 339 of the native cystathionine gamma lyase, said substitutions being i) E59V, ii) R119L and iii) E339V.

12. The nucleic acid of claim 1 , wherein the encoded polypeptide comprises amino acid substitutions at each of amino acid of positions 59, 119 and 339 of the native cystathionine gamma lyase, said substitutions being i) E59N, ii) R119L and iii) E339V.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2024
From: AEMASE, INC.
To: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 068786/0850 →
CONFIRMATORY LICENSE Recorded Mar 15, 2016
From: UNIVERSITY OF TEXAS, AUSTIN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 038089/0982 →
Continuity (3)
Division 13020268 · Feb 3, 2011
Provisional Application 61301368 · Feb 4, 2010
Related Publication 20140287484A1 · Sep 25, 2014